Raptor Pharmaceutical Corp.NASDAQ
Advanced Chart
  • Mon, Sep. 12, 7:32 AM
    • Horizon Pharma (NASDAQ:HZNP) acquires Raptor Pharmaceuticals (NASDAQ:RPTP) for $9 a share in cash ($800M). The deal, to be  financed with debt and cash, should close in Q4.
    • Raptor's leading products are PROCYSBI (cysteamine bitartrate) delay-release capsules for the treatment of a rare metabolic disorder called nephropathic cystinosis and QUINSAIR (aerosolized levofloxacin) for the management of chronic pulmonary infections. Its revenue guidance for this year is $125M - 135M.
    • Raptor closed Friday at $7.45.
    | Mon, Sep. 12, 7:32 AM | 4 Comments
  • Thu, Aug. 18, 8:46 AM
    • Raptor Pharmaceuticals (NASDAQ:RPTP) is ahead 16% premarket on robust volume on the buzz that several companies are eyeing the Novato, CA firm, including Shire plc (NASDAQ:SHPG) who alleged has already bid $800M and Retrophin (NASDAQ:RTRX), founded by biotech bad boy Martin Shkreli.
    • Raptor focuses its development efforts in rare diseases. Its pipeline includes programs in Huntington's disease, cancer, cystic fibrosis and mitochondrial diseases.
    • It currently markets two products: PROCYSBI (cysteamine bitartrate) delayed-release capsules for nephropathic cystinosis and QUINSAIR (aerosolized form of levofloxacin) for the management of chronic pulmonary infections.
    | Thu, Aug. 18, 8:46 AM | 2 Comments
  • Jan. 14, 2015, 9:42 AM
    • In an all-stock transaction, privately-held Tobira Therapeutics will merge with a wholly-owned subsidiary of Regado Biosciences (RGDO +59.3%). The combined organization, renamed as Tobira Therapeutics, will focus on the development of novel treatments for liver and inflammatory diseases. Tobira CEO Laurent Fischer, M.D., will lead the firm.
    • Tobira's lead product is cenicriviroc (CVC), a Fast Track-designated anti-fibrotic agent currently in Phase 2 development for non-alcoholic steatohepatitis (NASH).
    • A Tobira investor syndicate has committed to invest up to $22M to fund CVC's development through Phase 2. Tobira's quick asset balance will be ~$60M after the investment.
    • Under the terms of the merger, Regado shareholders will own ~32% of the combined entity while Tobira shareholders will own ~68%. The specific allocation will depend on Regado's net cash balance at the time of the transaction.
    | Jan. 14, 2015, 9:42 AM | 5 Comments